Endoscopic Ultrasound-guided Radiofrequency Ablation of Pancreatic Cysts (ERASE)

Pancreatic Cyst Clinical Trial

— ERASE  

Official title:

EUS-Guided Radiofrequency Ablation of Pancreatic Cysts - A Safety and Efficacy Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05916846
• Other study ID #: 2023C0004
• Status: Recruiting
• Phase: N/A
• Start date: April 24, 2023
• Est. completion date: April 30, 2026

Study information

• Verified date: June 2023
• Source: Ohio State University
• Contact: Somashekar G Krishna, MD, MPH
• Phone: 614-366-8716
• Email: somashekar.krishna[@]osumc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A single-center study to determine the safety and efficacy of EUS-guided radiofrequency ablation (RFA) of pancreatic cystic neoplasms (PCNs). Patients will be recruited sequentially to undergo RFA followed by standard surveillance. The study will recruit patients with pancreatic cystic lesions (PCLs) who are at high risk for surgical resection. Patients enrolled in the study will be followed up for 3-years after EUS-guided RFA.

Description:

This is a single-center prospective study evaluating EUS-guided RFA of PCNs (Figure 1). The study plans to enroll patients over a 3-year duration. Patients with a definitive diagnosis of a PCN and with prohibitive risks for surgery will be recruited sequentially to undergo EUS-guided RFA followed by standard of care surveillance.

The following assessments will be completed. Pre-recruitment radiological and EUS investigations should be performed within 3-6 months of planned enrollment and treatment. The pre-recruitment evaluation is part of the routine standard of care (SOC) assessment of PCNs.

• Pre-treatment/ Baseline These are standard of care practices for management of PCNs defined by International Consensus Guidelines (ICG) and American College of Gastroenterology PCL Guidelines.

Pre-treatment requirements:

1. MRI/MRCP (month -6 to day 0). Imaging will not be performed if already available as part of standard of practice in managing PCLs 2. Pancreatic protocol CT abdomen (month -6 to day 0) (if a patient cannot undergo MRI/MRCP) 3. Physical examination (including ECOG (Eastern Cooperative Oncology Group) performance status) 4. Laboratory: Complete Blood Count (CBC), Basic Metabolic Panel (BMP), Liver Function Tests (LFTs), Prothrombin Time (PT) Test & International Normalised Ratio (INR) blood test, serum CA19-9 (cancer antigen 19-9), serum amylase, lipase, Chromogranin A (for cystic-NET). Laboratory tests will not be performed if already available as part of the standard of practice in managing PCLs and standard of care prior to routine EUS-FNA (fine needle aspiration).

5. EUS with FNA (as per ICG) with at least one of the following advanced diagnostics - EUS-nCLE (needle-guided confocal laser endomicroscopy) or cyst fluid analysis by NGS (Next-generation sequencing).

6. Experimental arm: Cyst fluid will also be sent for pre-treatment flow cytometry for immunological markers of antineoplastic response (baseline)

• Treatment (Day 0):

1. Physical examination

2. Informed consent

3. Pregnancy tests when indicated, will not be performed if already available as part of the standard of practice in managing PCLs and standard of care prior to routine EUS-FNA.

4. Administration of pre-procedure prophylaxis against post-EUS-RFA pancreatitis. This is the standard prophylaxis used to prevent pancreatitis during ERCP (Endoscopic retrograde cholangiopancreatography) procedures. This will involve Ringers Lactate as choice of IV fluid, per rectal indomethacin administered during the procedure, and only clear liquid diet is permitted post-procedure (till next morning).

5. One dose IV quinolone antibiotic (or equivalent if patient has allergy to quinolones)

6. Anesthesia: The standard of practice anesthesia required for any EUS procedure will be applied during the procedure. Anesthesia can be either Monitored Anesthesia Care (MAC) or general. As per standard practice, all patients referred for EUS will undergo nursing triage. If and when indicated, patients will be referred to OSU Preoperative Assessment Clinic (OPAC) for review by anesthesia prior to the procedure.

7. EUS-FNA (if sufficient send for cyst fluid analysis as per SOC) and EUS-RFA of PCN

8. Inpatient admission for overnight observation

9. Apply AGREE classification for adverse events, document only Grade II and above since patients are admitted for observation

10. If patient has post-procedure acute pancreatitis, document severity based on Revised Atlanta Classification

• Post-procedure day # 1:

1. Symptom and adverse event monitoring - AGREE classification and Revised Atlanta Classification (Appendix 3) in patients with acute pancreatitis 2. Physical examination

3. Laboratory: CBC, BMP, LFTs, Lipase on post-procedure day # 1

• Follow-up & response assessment These are standard of care practices for the management of PCNs defined by International Consensus Guidelines (ICG)3 and/or American College of Gastroenterology Guidelines.21

For cyst ≥ 3 cm, follow-up is every 3-6 months 1. Physical examination (including ECOG (performance status) 2. Imaging with MRI/MRCP or CT abdomen (pancreatic protocol) For cysts < 3 cm, follow-up is every 6-12 months

1. Physical examination (including ECOG performance status)

2. Imaging with MRI/MRCP or CT abdomen (pancreatic protocol) For all cysts

1. Alternate MRI/MRCP (or CT imaging) with EUS every 6 months to 1 year (SOC, ICG cyst guidelines) Total duration of follow-up

1. Indefinitely as per standard of care in patients with pancreatic cysts (SOC, ICG cyst guidelines)

2. 3 calendar years of documentation for study purposes

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: April 30, 2026
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age >18 years.

2. A diagnosis of a PCN confirmed by EUS-FNA including cyst fluid NGS and/or EUS-nCLE and/or EUS-TTNB (through the needle biopsy).

3. The PCL measures at least 2 cm in diameter on either CT or MRI/MRCP or EUS and demonstrates concerning worrisome and/or high-risk features as defined by International Consensus Guidelines (2017 revised Fukuoka Guidelines).

4. The patient is not a surgical candidate after consultation with Hepato-Pancreato-Biliary (HPB) surgery and/or review in the pancreatic multi-disciplinary tumor board conference.

Common clinical scenarios include -

1. Cirrhosis of the liver (common clinical scenario)

2. Advanced age (common clinical scenario)

3. Morbid obesity

4. Significant cardiorespiratory comorbidity

5. Patient's choice (patient elects for non-surgical management)

6. Other significant comorbid conditions that impose prohibitive surgical risks

5. Estimated life expectancy of at least 1 year.

6. Capable of giving written informed consent.

7. Women of childbearing potential must have a negative pregnancy test (serum/urine) on the day of treatment. Pregnancy testing is the routine standard of care practice in the endoscopy laboratory for all patients undergoing endoscopy and sedation for endoscopy.

8. The patient prefers non-surgical management after consultation with Hepato-Pancreato-Biliary (HPB) surgery

9. The patient is not a surgical candidate and has had prior attempts at ablation of the PCN by EUS-guided injection of chemotherapy (OSU IRB protocol 2020C0198)

Exclusion Criteria:

1. A diagnosis of a benign or non-neoplastic PCL such as a pseudocyst confirmed by EUS-FNA including cyst fluid NGS and/or EUS-nCLE and/or EUS-TTNB.

2. A diagnosis of a malignant PCN confirmed by evidence of adenocarcinoma and/or invasive carcinoma and/or distant metastases

3. Cysts or NETS (neuroendocrine tumors) involving or in close proximity to blood vessels or the biliary tree where the zone of ablation is likely to compromise these structures.

4. PCNs such as IPMNs involving the main pancreatic duct as in mixed-IPMN lesions.

5. Acute pancreatitis in the preceding 4 weeks prior to date of EUS-RFA

6. Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it unsafe for the patient to participate in the study.

7. Any psychiatric disorder making reliable informed consent impossible.

8. Pregnancy or breast-feeding.

9. ECOG performance status 4.

10. Contraindication to general anesthesia after review by OSU Preoperative Assessment Clinic (OPAC)

11. Cardiac Implantable Electrical Devices

Related Conditions & MeSH terms

• Cysts
• Pancreatic Cyst
• Radiofrequency Ablation

Intervention

Procedure:
• EUS-guided radiofrequency ablation of pancreatic cyst
EUS-RFA is performed with an 19 Gauge RFA needle (STARMed/TaeWoong Medical USA) applying up to 30 Watt (W) current with Continuance Mode setting. RFA confirmation is confirmed endoscopically via EUS (white bubbles on EUS imaging) and impedance monitoring on the VIVA™ Combo System. Impedance has a maximum value up 800 Ohms. Sequential doses of electrical energy at 10W-30W are applied to ablate the PCN.

Device:
• FDA-cleared device (EUS-RFA probe)
FDA-cleared device (EUS-RFA probe).

Locations

Country	Name	City	State
United States	The Ohio State University Wexner Medical Center	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Ohio State University

Country where clinical trial is conducted

United States, 

References & Publications (44)

Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, Pilotto A, Forlano R. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007 Aug;102(8):1781-8. doi: 10.1111/j.1572-0241.2007.01279.x. Epub 2007 May 17. — View Citation

Barthet M, Giovannini M, Gasmi M, Lesavre N, Boustiere C, Napoleon B, LaQuiere A, Koch S, Vanbiervliet G, Gonzalez JM. Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms. Endosc Int Open. 2021 Aug;9(8):E1178-E1185. doi: 10.1055/a-1479-2199. Epub 2021 Jul 16. — View Citation

Barthet M, Giovannini M, Lesavre N, Boustiere C, Napoleon B, Koch S, Gasmi M, Vanbiervliet G, Gonzalez JM. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy. 2019 Sep;51(9):836-842. doi: 10.1055/a-0824-7067. Epub 2019 Jan 22. — View Citation

Bellizzi AM, Stelow EB. Pancreatic cytopathology: a practical approach and review. Arch Pathol Lab Med. 2009 Mar;133(3):388-404. doi: 10.5858/133.3.388. — View Citation

Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995 Apr 22;345(8956):1008-12. doi: 10.1016/s0140-6736(95)90755-6. — View Citation

Brugge WR, Lewandrowski K, Lee-Lewandrowski E, Centeno BA, Szydlo T, Regan S, del Castillo CF, Warshaw AL. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004 May;126(5):1330-6. doi: 10.1053/j.gastro.2004.02.013. — View Citation

Celikoglu SI, Celikoglu F, Goldberg EP. Endobronchial intratumoral chemotherapy (EITC) followed by surgery in early non-small cell lung cancer with polypoid growth causing erroneous impression of advanced disease. Lung Cancer. 2006 Dec;54(3):339-46. doi: 10.1016/j.lungcan.2006.09.004. Epub 2006 Oct 11. — View Citation

Chang KJ, Nguyen PT, Thompson JA, Kurosaki TT, Casey LR, Leung EC, Granger GA. Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound-guided fine-needle injection in patients with advanced pancreatic carcinoma. Cancer. 2000 Mar 15;88(6):1325-35. doi: 10.1002/(sici)1097-0142(20000315)88:63.0.co;2-t. — View Citation

Chang YR, Park JK, Jang JY, Kwon W, Yoon JH, Kim SW. Incidental pancreatic cystic neoplasms in an asymptomatic healthy population of 21,745 individuals: Large-scale, single-center cohort study. Medicine (Baltimore). 2016 Dec;95(51):e5535. doi: 10.1097/MD.0000000000005535. — View Citation

Choi JH, Seo DW, Song TJ, Park DH, Lee SS, Lee SK, Kim MH. Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors. Endoscopy. 2018 Nov;50(11):1099-1104. doi: 10.1055/a-0583-8387. Epub 2018 May 4. — View Citation

Crino SF, D'Onofrio M, Bernardoni L, Frulloni L, Iannelli M, Malleo G, Paiella S, Larghi A, Gabbrielli A. EUS-guided Radiofrequency Ablation (EUS-RFA) of Solid Pancreatic Neoplasm Using an 18-gauge Needle Electrode: Feasibility, Safety, and Technical Success. J Gastrointestin Liver Dis. 2018 Mar;27(1):67-72. doi: 10.15403/jgld.2014.1121.271.eus. — View Citation

Crippa S, Fernandez-del Castillo C. A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg. 2007 May;245(5):826-7; author reply 527-8. doi: 10.1097/01.sla.0000261153.24610.ec. No abstract available. — View Citation

Elta GH, Enestvedt BK, Sauer BG, Lennon AM. ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol. 2018 Apr;113(4):464-479. doi: 10.1038/ajg.2018.14. Epub 2018 Feb 27. — View Citation

Gan SI, Thompson CC, Lauwers GY, Bounds BC, Brugge WR. Ethanol lavage of pancreatic cystic lesions: initial pilot study. Gastrointest Endosc. 2005 May;61(6):746-52. doi: 10.1016/s0016-5107(05)00320-2. — View Citation

Giardino A, Innamorati G, Ugel S, Perbellini O, Girelli R, Frigerio I, Regi P, Scopelliti F, Butturini G, Paiella S, Bacchion M, Bassi C. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. Pancreatology. 2017 Nov-Dec;17(6):962-966. doi: 10.1016/j.pan.2017.09.008. Epub 2017 Sep 27. — View Citation

Hader WJ, Steinbok P, Hukin J, Fryer C. Intratumoral therapy with bleomycin for cystic craniopharyngiomas in children. Pediatr Neurosurg. 2000 Oct;33(4):211-8. doi: 10.1159/000055955. — View Citation

Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003 Feb;9(2):555-61. — View Citation

Kamboj AK, Dewitt JM, Modi RM, Conwell DL, Krishna SG. Confocal Endomicroscopy Characteristics of Different Intraductal Papillary Mucinous Neoplasm Subtypes. JOP. 2017 May;18(Suppl 2):198-202. — View Citation

Krishna SG, Brugge WR, Dewitt JM, Kongkam P, Napoleon B, Robles-Medranda C, Tan D, El-Dika S, McCarthy S, Walker J, Dillhoff ME, Manilchuk A, Schmidt C, Swanson B, Shah ZK, Hart PA, Conwell DL. Needle-based confocal laser endomicroscopy for the diagnosis of pancreatic cystic lesions: an international external interobserver and intraobserver study (with videos). Gastrointest Endosc. 2017 Oct;86(4):644-654.e2. doi: 10.1016/j.gie.2017.03.002. Epub 2017 Mar 10. Erratum In: Gastrointest Endosc. 2018 Jun;87(6):1599. — View Citation

Krishna SG, Hart PA, DeWitt JM, DiMaio CJ, Kongkam P, Napoleon B, Othman MO, Yew Tan DM, Strobel SG, Stanich PP, Patel A, Luthra AK, Chan MQ, Blaszczak AM, Lee D, El-Dika S, McCarthy ST, Walker JP, Arnold CA, Porter K, Conwell DL. EUS-guided confocal laser endomicroscopy: prediction of dysplasia in intraductal papillary mucinous neoplasms (with video). Gastrointest Endosc. 2020 Mar;91(3):551-563.e5. doi: 10.1016/j.gie.2019.09.014. Epub 2019 Sep 19. — View Citation

Krishna SG, Hart PA, Malli A, Kruger AJ, McCarthy ST, El-Dika S, Walker JP, Dillhoff ME, Manilchuk A, Schmidt CR, Pawlik TM, Porter K, Arnold CA, Cruz-Monserrate Z, Conwell DL. Endoscopic Ultrasound-Guided Confocal Laser Endomicroscopy Increases Accuracy of Differentiation of Pancreatic Cystic Lesions. Clin Gastroenterol Hepatol. 2020 Feb;18(2):432-440.e6. doi: 10.1016/j.cgh.2019.06.010. Epub 2019 Jun 18. — View Citation

Machicado JD, Chao WL, Carlyn DE, Pan TY, Poland S, Alexander VL, Maloof TG, Dubay K, Ueltschi O, Middendorf DM, Jajeh MO, Vishwanath AB, Porter K, Hart PA, Papachristou GI, Cruz-Monserrate Z, Conwell DL, Krishna SG. High performance in risk stratification of intraductal papillary mucinous neoplasms by confocal laser endomicroscopy image analysis with convolutional neural networks (with video). Gastrointest Endosc. 2021 Jul;94(1):78-87.e2. doi: 10.1016/j.gie.2020.12.054. Epub 2021 Jan 16. — View Citation

Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992 Sep;10(9):1485-91. doi: 10.1200/JCO.1992.10.9.1485. — View Citation

Megibow AJ, Baker ME, Morgan DE, Kamel IR, Sahani DV, Newman E, Brugge WR, Berland LL, Pandharipande PV. Management of Incidental Pancreatic Cysts: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2017 Jul;14(7):911-923. doi: 10.1016/j.jacr.2017.03.010. Epub 2017 May 19. — View Citation

Moayyedi P, Weinberg DS, Schunemann H, Chak A. Management of pancreatic cysts in an evidence-based world. Gastroenterology. 2015 Apr;148(4):692-5. doi: 10.1053/j.gastro.2015.02.035. Epub 2015 Feb 24. No abstract available. — View Citation

Moyer MT, Dye CE, Sharzehi S, Ancrile B, Mathew A, McGarrity TJ, Gusani N, Yee N, Wong J, Levenick J, Dougherty-Hamod B, Mathers B. Is alcohol required for effective pancreatic cyst ablation? The prospective randomized CHARM trial pilot study. Endosc Int Open. 2016 May;4(5):E603-7. doi: 10.1055/s-0042-105431. Epub 2016 May 10. — View Citation

Ofosu A, Ramai D, Adler DG. Endoscopic ultrasound-guided ablation of pancreatic cystic neoplasms: ready for prime time? Ann Gastroenterol. 2019 Jan-Feb;32(1):39-45. doi: 10.20524/aog.2018.0331. Epub 2018 Dec 3. — View Citation

Oh HC, Seo DW, Song TJ. Resolution of a septated pancreatic cyst by booster endoscopic ultrasonography-guided ablation. J Dig Dis. 2011 Dec;12(6):497-9. doi: 10.1111/j.1751-2980.2011.00538.x. No abstract available. — View Citation

Oleinikov K, Dancour A, Epshtein J, Benson A, Mazeh H, Tal I, Matalon S, Benbassat CA, Livovsky DM, Goldin E, Gross DJ, Jacob H, Grozinsky-Glasberg S. Endoscopic Ultrasound-Guided Radiofrequency Ablation: A New Therapeutic Approach for Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2637-2647. doi: 10.1210/jc.2019-00282. — View Citation

Pai M, Habib N, Senturk H, Lakhtakia S, Reddy N, Cicinnati VR, Kaba I, Beckebaum S, Drymousis P, Kahaleh M, Brugge W. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg. 2015 Apr 27;7(4):52-9. doi: 10.4240/wjgs.v7.i4.52. — View Citation

Paiella S, Salvia R, Ramera M, Girelli R, Frigerio I, Giardino A, Allegrini V, Bassi C. Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review. Gastroenterol Res Pract. 2016;2016:4508376. doi: 10.1155/2016/4508376. Epub 2016 Feb 15. — View Citation

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155. Erratum In: Cancer Res. 2014 Jul 15;74(14):4006. — View Citation

Reid-Lombardo KM, St Sauver J, Li Z, Ahrens WA, Unni KK, Que FG. Incidence, prevalence, and management of intraductal papillary mucinous neoplasm in Olmsted County, Minnesota, 1984-2005: a population study. Pancreas. 2008 Aug;37(2):139-44. doi: 10.1097/MPA.0b013e318162a10f. — View Citation

Ren R, Krishna SG, Chen W, Frankel WL, Shen R, Zhao W, Avenarius MR, Garee J, Caruthers S, Jones D. Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation. Mod Pathol. 2021 Feb;34(2):438-444. doi: 10.1038/s41379-020-00647-z. Epub 2020 Aug 13. — View Citation

Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015 Apr;148(4):824-48.e22. doi: 10.1053/j.gastro.2015.01.014. No abstract available. — View Citation

Scopelliti F, Pea A, Conigliaro R, Butturini G, Frigerio I, Regi P, Giardino A, Bertani H, Paini M, Pederzoli P, Girelli R. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Surg Endosc. 2018 Sep;32(9):4022-4028. doi: 10.1007/s00464-018-6217-x. Epub 2018 May 15. — View Citation

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7. — View Citation

Song TJ, Seo DW, Lakhtakia S, Reddy N, Oh DW, Park DH, Lee SS, Lee SK, Kim MH. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Gastrointest Endosc. 2016 Feb;83(2):440-3. doi: 10.1016/j.gie.2015.08.048. Epub 2015 Sep 4. — View Citation

Stark A, Donahue TR, Reber HA, Hines OJ. Pancreatic Cyst Disease: A Review. JAMA. 2016 May 3;315(17):1882-93. doi: 10.1001/jama.2016.4690. — View Citation

Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, Salvia R, Shimizu Y, Tada M, Wolfgang CL. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017 Sep-Oct;17(5):738-753. doi: 10.1016/j.pan.2017.07.007. Epub 2017 Jul 13. — View Citation

van der Waaij LA, van Dullemen HM, Porte RJ. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc. 2005 Sep;62(3):383-9. doi: 10.1016/s0016-5107(05)01581-6. — View Citation

Vege SS, Ziring B, Jain R, Moayyedi P; Clinical Guidelines Committee; American Gastroenterology Association. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015 Apr;148(4):819-22; quize12-3. doi: 10.1053/j.gastro.2015.01.015. No abstract available. — View Citation

Yoon WJ, Lee JK, Lee KH, Ryu JK, Kim YT, Yoon YB. Cystic neoplasms of the exocrine pancreas: an update of a nationwide survey in Korea. Pancreas. 2008 Oct;37(3):254-8. doi: 10.1097/MPA.0b013e3181676ba4. — View Citation

Zerboni G, Signoretti M, Crippa S, Falconi M, Arcidiacono PG, Capurso G. Systematic review and meta-analysis: Prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals. Pancreatology. 2019 Jan;19(1):2-9. doi: 10.1016/j.pan.2018.11.014. Epub 2018 Nov 28. — View Citation

* Note: There are 44 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the efficacy of EUS-RFA post-procedure after one year	1) Significant ablation: Defined as at least a 50% decrease in the cyst diameter measured in millimeters (mm).; i) Cross-sectional imaging and EUS; (1) Change in the diameter, measured in millimeters (mm); AND/OR; 2) Resolution of pathogenic mutations ii) Cyst fluid aspiration; (1) NGS - Persistence or absence of mutations (molecular markers)	At one calendar year after EUS-RFA procedure
Secondary	Incidence of adverse events	Assess the safety of EUS-guided RFA of PCNs.; Documented using the AGREE classification, Grade 2 or above, for adverse events in gastrointestinal advanced endoscopy.; Presence or absence of post-procedure acute pancreatitis, document severity based on Revised Atlanta Classification.	Time point 1: Immediately post-procedure (after EUS-RFA) in endoscopy unit up to 24 hours after procedure; Time point 2: At one calendar year after EUS-RFA
Secondary	Assess the long-term response to EUS-RFA for efficacy of significant and durable ablation response	Durable response: Continued response with further decrease in cyst diameter beyond the first calendar year.; AND/OR; Significant ablation: Defined as at least a 50% decrease in the cyst diameter measured in millimeters (mm).; i) Cross-sectional imaging and EUS; (1) Change in the diameter, measured in millimeters (mm); AND/OR; ) Resolution of pathogenic mutations ii) Cyst fluid aspiration; (1) NGS - Persistence or absence of mutations (molecular markers)	At two and three calendar years after EUS-RFA